Effects of Omega-3 Fatty Acids on Markers of Inflammation

Obesity Clinical Trial

Official title:

Effects of Plant and Marine Omega-3 (w-3) Fatty Acids on Inflammatory Markers In Insulin Resistant Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01129050
• Other study ID #: SU-05042010-5842
• Secondary ID: R21AT003465-01
• Status: Completed
• Phase: N/A
• Start date: April 2007
• Est. completion date: December 2008

Study information

• Verified date: February 2023
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The major purpose of this study is to examine the effect of two sources of dietary omega-3 fatty acids, each given at two doses, on potential health benefits related to cardiovascular disease prevention. The two sources of dietary omega-3 fatty acids will be fish oil, and flaxseed oil.

Description:

The primary aim of this study is to examine the effect of two sources of dietary omega-3 fatty acids, each given at two doses, on potential health benefits related to cardiovascular disease prevention. The two sources of dietary omega-3 fatty acids will be fish oil, and flaxseed oil. Each will be given at a lower dose that could realistically be achieved from food sources alone, and at a higher dose that could not realistically be achieved from food alone and would require supplementation. The outcomes being studied are markers of inflammation. The subjects being studied are those with elevated risk factors for diabetes and heart disease that meet the criteria for the "metabolic syndrome". These are the people who are currently not diabetic, and who have not been diagnosed yet with heart disease, who are at risk of developing these diseases and who would likely benefit the most from the omega-3 therapy should it prove to be effective.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 102
• Est. completion date: December 2008
• Est. primary completion date: December 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:Gender:

• Both women and men
• Age: > or = 18 years
• Ethnicity and race: All ethnic and racial backgrounds welcome
• As defined in ATP III of the National Cholesterol Education program, the metabolic syndrome will be diagnosed as presence of at least three of the following, which will be measured at the screening clinic visit:

Central obesity as measured by waist circumference:

• Men: Greater than 40 inches
• Women: Greater than 35 inches
• Fasting blood triglycerides greater than or equal to 150 mg/dL
• Blood HDL cholesterol:
• Men: Less than 40 mg/dL
• Women: Less than 50 mg/dL
• Blood pressure greater than or equal to 130/85 mmHg
• Fasting glucose greater than or equal to 100 mg/dL Planning to be available for clinic visits and bottle pick-ups for the 8 weeks of study participation Ability and willingness to give written informed consent No known active psychiatric illness. Exclusion Criteria:Daily intake of dietary supplements containing omega-3 FAs within the past month.
• Fasting blood glucose > 140 mg/dL
• Significant liver enzyme abnormality
• AST or ALT more than 2 times the upper limit of normal and/or
• Bilirubin more than 50% the upper limit of normal
• Renal disease as measured at baseline:
• Serum creatinine > 1.30 mg/dL, or
• Calculated creatinine clearance < 71 mL/min
• Self reported personal history of:
• Clotting disorders
• Clinically significant atherosclerosis (e.g., CAD, PAD)
• Malignant neoplasm
• Ongoing infection
• Inflammatory disease (e.g., rheumatoid arthritis)
• Subjects currently receiving the following medications (self report):
• Anti-Inflammatory drugs
• Lipid lowering drugs including statins
• Anti-hypertensive drugs
• Anti-coagulant drugs
• Body Mass Index (BMI) greater than or equal to 40.
• Pregnant or Lactating
• Inability to communicate effectively with study personnel

Related Conditions & MeSH terms

• Hypertension
• Hypertriglyceridemia
• Insulin Resistance
• Obesity

Intervention

Dietary Supplement:
• Fish Oil
Fish oil capsule
• Flaxseed Oil
Flaxseed oil capsule
• Placebo
Soybean oil capsule

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Stanford University	National Center for Complementary and Integrative Health (NCCIH)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Dewell A, Marvasti FF, Harris WS, Tsao P, Gardner CD. Low- and high-dose plant and marine (n-3) fatty acids do not affect plasma inflammatory markers in adults with metabolic syndrome. J Nutr. 2011 Dec;141(12):2166-71. doi: 10.3945/jn.111.142240. Epub 201 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in inflammatory markers (MCP-1, IL-6, and sICAM-1) at 8 weeks.	Change was calculated as the value at 8 weeks minus the value at baseline	Baseline and 8 weeks
Secondary	Change from baseline in red blood cells (RBC) Fatty Acids at 8 weeks.	Change was calculated as the value at 8 weeks minus the value at baseline	Baseline and 8 weeks
Secondary	Change from baseline in low-density lipoprotein (LDL) cholesterol at 8 weeks.	Change was calculated as the value at 8 weeks minus the value at baseline	Baseline and 8 weeks
Secondary	Change from baseline in high-density lipoprotein (HDL) cholesterol at 8 weeks.	Change was calculated as the value at 8 weeks minus the value at baseline	Baseline and 8 weeks
Secondary	Change from baseline in triglycerides at 8 weeks.	Change was calculated as the value at 8 weeks minus the value at baseline	Baseline and 8 weeks

External Links

•   Study description and summary of results